¹ú²ú¾«Æ·×ÔÔÚÔÚÏßÎçÒ¹Ãâ·Ñ

Global Heparin Industrial Chain

Techdow has a fully integrated global operation covering the entire heparin industrial chain, from the supply of raw materials and the manufacturing of APIs, to the scaled manufacturing of enoxaparin preparations. Techdow is among the few Chinese biopharmaceutical companies with a globally integrated close-loop operation in all parts of the heparin industrial chain. Techdow's integrated supply chain management system, designed to deliver traceability, quality, and reliable supply of raw materials, can ensure high product yield and quality.

Slide left and right to view the picture

Approved Clinical Indication for Enoxaparin

1 drug adopted for treatment in

Enoxaparin sodium injection

4 therapeutic areas

  • Prophylaxis of VTE diseases£º

    Prophylaxis of VTE in hip arthroplasty 

    Prophylaxis of VTE in knee arthroplasty 

    Prophylaxis of VTE in total hip arthroplasty (THA) 

    Prophylaxis of VTE in orthopedic trauma 

    Prophylaxis of VTE in pelvic surgery 

    Prophylaxis of VTE in general surgery 

    Prophylaxis of VTE in medical treatment

  • Treatment of existing ¶Ù³Õ°Õ£º

    DVT anticoagulant therapy with or without pulmonary embolism

    Extended treatment of DVT and pulmonary embolism (PE) and prevention of its recurrence in patients with active cancer

  • ±·³§°Õ·¡-´¡°ä³§£º

    Anticoagulant in the treatment of unstable angina / non-Q wave myocardial infarction

    Anticoagulant in PCI treatment

    ³§°Õ·¡²Ñ±õ£º

    Anticoagulant in the medical treatment of STEMI

    Anticoagulant in PCI treatment

  • ±á±ð³¾´Ç»å¾±²¹±ô²â²õ¾±²õ£º

    Prevention of thrombosis in the extra-corporeal circulation of hemodialysis

  • ³Õ°Õ·¡£ºvenous thromboembolism
  • ¶Ù³Õ°Õ£ºdeep venous thrombosis
  • ±·³§°Õ·¡-´¡°ä³§£ºNon-ST elevation-acute coronary syndrome
  • ³§°Õ·¡²Ñ±õ£ºST-segment elevation myocardial infarction
  • ±Ê°ä±õ£ºpercutaneous coronary intervention

Clinical Applications of Enoxaparin

  • Respiratory Diseases

    Clinical Applications

    Patients with severe COVID-19 infections and those hospitalized for the infection 

    Patients with acute diseases including impaired respiratory functions or severe infections 

    Patients with deep venous thrombosis or pulmonary embolism (PE), excluding those PE patients who may need thrombolytic therapy or surgical treatment

  • Gastroenterology

    Clinical Applications

    High thrombotic risk patients receiving high-risk endoscopic surgeries

  • Hematology

    Clinical Applications

    Acute lymphocytic leukemia 

    Cancer patients with thrombocytopenia 

    Rare hereditary hemorrhagic diseases

  • Cardiology

    Clinical Applications

    Unstable angina 

    Non-ST-elevated myocardial infarction 

    Acute ST-elevated myocardial infarction 

    Acute heart failure patients on medical treatment 

    Hospitalized patients with atrial fibrillation 

    ICU-treated COVID-19 infected patients with underlying heart diseases or prior cardiovascular events 

    Pregnant women with heart diseases

  • Gynecology & Obstetrics

    Clinical Applications

    Pregnant women with heart diseases 

    Potential Applications* :
    - Recurrent spontaneous abortion
    - Antiphospholipid syndrome
    - Prethrombotic state

  • Neurology

    Clinical Applications

    Patients with brain tumors 

    Transient ischemic attacks

  • Surgery

    Clinical Applications

    Patients with mid/high VTE risks receiving:
    - Orthopedic surgery
    - General surgical treatment
    - Surgical cancer treatment

  • Cancer

    Clinical Applications

    Cancer patients with venous thromboembolism (VTE) 

    Cancer patients with thrombocytopenia

  • Transplants

    Clinical Applications

    Patients awaiting or received liver transplants

  • Medical Nephrology & Dialysis

    Clinical Applications

    Chronic kidney disease patients with VTE 

    Extracorporeal circulation during dialysis 

    Rheumatic disease patients with VTE

Legal statement   ¡¤   Environmental Disclosure

Copyright ?2022 Shenzhen Techdow Pharmaceutical Co., Ltd